1. What Is the Uveitis Market?
The Uveitis Market covers the anti-inflammatory and the immunosuppressive treatments for the intraocular inflammation of the anterior, intermediate, posterior, and panuveitis. The infectious and non-infectious aetiologies including sarcoidosis, Behcet's disease, birdshot retinochoroidopathy, the HLA-B27-associated uveitis, and the idiopathic posterior uveitis create the inflammation through the intraocular immune activation. The activation threatens the sight from the cystoid macular oedema, the optic nerve involvement, the retinal vasculitis, and the structural complications that the chronic inflammation produces. Uveitis pharmacological treatment uses the topical, the periocular, and the systemic corticosteroid for the acute inflammation control. The antimetabolites methotrexate and mycophenolate and the calcineurin inhibitors cyclosporine and tacrolimus provide the steroid-sparing maintenance. The biologic adalimumab gained the FDA approval for the non-infectious intermediate, posterior, and panuveitis in 2016. The uveitis market is advancing with the gevokizumab anti-IL-1 beta antibody for the Behcet's disease posterior uveitis and the secukinumab anti-IL-17 antibody for the HLA-B27-associated uveitis where the IL-17 pathway drives the ocular inflammation.
2. Uveitis Market Size & Forecast
3. Emerging Technologies
- Adalimumab VISUAL I and VISUAL II Phase III trials demonstrated the 50 and 68 percent reduction in the treatment failure rate compared with placebo. The trials enrolled the active and the inactive non-infectious uveitis patients on corticosteroid taper. The trials established the anti-TNF biologic as the first FDA-approved systemic therapy for the non-infectious intermediate, posterior, and panuveitis. The biologic provides the steroid-sparing treatment for the sight-threatening inflammatory disease.
- Fluocinolone acetonide intravitreal implant Iluvien and Yutiq provide the 36-month sustained corticosteroid release from the non-biodegradable implant. The implant releases the 0.18 to 0.19 micrograms per day of the corticosteroid directly to the posterior segment. The implant provides the sustained posterior uveitis suppression without the systemic corticosteroid exposure that the intravitreal localised delivery achieves.
- Behcet's disease uveitis management uses the colchicine for the mucocutaneous manifestations and the azathioprine for the ocular involvement. The anti-TNF infliximab and adalimumab treat the severe posterior uveitis and the retinal vasculitis. The highest vision threat that Behcet's creates requires the aggressive biologic treatment for the macular and the optic nerve-threatening inflammation.
- Vorolanib oral VEGF-TK and JAK inhibitor combination in phase II addresses the macular oedema complicating the uveitis. The combination provides the anti-inflammatory and the anti-angiogenic dual mechanism approach. The approach targets the complication of chronic uveitis.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Immunology Drug Market.
4. Key Market Opportunity
Within the Uveitis market, a leading opportunity is upadacitinib JAK inhibitor approval for non-infectious uveitis, where successful Phase III development could establish oral JAK uveitis therapy alternative to adalimumab. AbbVie advancing upadacitinib uveitis approval captures this opportunity. Adjacent demand centers on adalimumab biosimilar uveitis access expansion. As JAK uveitis approval progresses and biosimilar adalimumab access grows, the addressable opportunity is evolving from adalimumab and corticosteroid-dominant uveitis treatment toward broader systemic and oral options.
5. Top Companies in the Uveitis Market
The following organisations hold leading positions in the Uveitis Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie
- EyePoint Pharmaceuticals
- Santen Pharmaceutical
- Bausch + Lomb
- Aldeyra Therapeutics
- Clearside Biomedical
6. Market Segmentation
The Uveitis Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | TNF Inhibitor Corticosteroid Implant Immunomodulator JAK Inhibitor |
| By Setting | Anterior Intermediate Posterior Panuveitis |
| By Etiology | Non-Infectious Autoimmune Idiopathic Behcet |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Uveitis Market trajectory over the forecast period:
Adalimumab VISUAL I and VISUAL II Phase III 50 and 68 Percent Treatment Failure Rate Reduction in Active and Inactive Non-Infectious Uveitis Has Established the First FDA-Approved Systemic Biologic for Non-Infectious Posterior and Panuveitis That Provides Steroid-Sparing Sight-Saving Treatment.AbbVie's adalimumab Humira demonstrated 50% reduction in risk of treatment failure in VISUAL I for active non-infectious uveitis and 68% reduction in VISUAL II for inactive non-infectious uveitis with significant steroid-sparing, earning approval in 2016 as the first and currently only biologic approved for non-infectious intermediate, posterior, and panuveitis. The uveitis approval has been commercially modest relative to AbbVie's immunology indications due to the small patient population but clinically major in retaining vision in patients with refractory uveitis where cumulative corticosteroid toxicity from cataract, glaucoma, and systemic side effects had been the limiting factor in management. Adalimumab biosimilar entry in the uveitis indication has followed the broader adalimumab biosimilar market, and ophthalmologists have adopted biosimilars particularly in markets with mandatory non-medical switching policies.
Fluocinolone Acetonide Iluvien and Yutiq 36-Month Sustained Intravitreal Corticosteroid 0.18 to 0.19 Micrograms Per Day Release Has Provided the Posterior Segment Sustained Suppression Without Systemic Corticosteroid Exposure That the Localised Intravitreal Delivery Enables for Chronic Posterior Uveitis.Roche's tocilizumab intravenous demonstrated superiority over placebo in a small Phase 2 Japonese trial in Behcet uveitis, and sarilumab is in Phase 2 in non-infectious intermediate and posterior uveitis based on the mechanistic hypothesis that IL-6 drives macular oedema through vascular endothelial growth factor induction and lymphocyte activation in the uveal compartment. The ocular pharmacokinetics of systemic IL-6 receptor blockade in achieving therapeutic aqueous and vitreous drug concentrations has been a limiting factor in uveitis drug development where intravitreal routes achieve much higher intraocular concentrations than systemic administration but create injection burden that must be weighed against therapeutic benefit. Intravitreal tocilizumab delivery is being evaluated as a local approach that maximises intraocular IL-6 blockade while avoiding systemic immunosuppression in the uveitis population where infection risk is a clinical concern.
Behcet's Disease Severe Posterior Uveitis Anti-TNF Infliximab and Adalimumab Aggressive Biologic Treatment for the Macular and Optic Nerve-Threatening Retinal Vasculitis Has Established the High-Threat Ocular Behcet's as the Biologic-First Indication That Sight Preservation Requires.EyePoint's fluocinolone acetonide 0.18 mcg/day Yutiq implant demonstrated 4-year sustained steroid delivery from a single intravitreal insert that reduces the injection frequency burden of monthly anti-VEGF or quarterly steroid to a once-per-eye procedure, achieving uveitis recurrence reduction of 30% versus sham in the YOSEMITE trial. The low-dose continuous-release design of Yutiq delivers fluocinolone below the threshold of posterior subcapsular cataract and intraocular pressure elevation that high-dose depot triamcinolone causes, providing a tolerable long-duration delivery profile. Allergan's Ozurdex dexamethasone biodegradable implant provides a 6-month duration alternative to the 3-year Yutiq implant, enabling a shorter-commitment initial treatment that allows clinical reassessment before committing to the longer-duration implant in patients with uncertain uveitis disease activity trajectory.
For related market intelligence, see the Ophthalmology Drug Market.
8. Segmental Analysis
By drug class, the corticosteroid and immunosuppressant segment dominated the Uveitis Market in 2025, as local steroid implants from AbbVie and EyePoint Pharmaceuticals anchored treatment of non-infectious uveitis, generating the largest share of the indication's revenue.
By etiology, the non-infectious segment is projected to register the highest growth rate through 2034, as AbbVie's Humira and emerging targeted biologics expand treatment for refractory and sight-threatening disease that does not respond to steroids, addressing a leading cause of preventable blindness.
9. Regional Analysis
Regional demand patterns across the Uveitis Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Uveitis Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for adalimumab uveitis and corticosteroid intravitreal implants and the established uveitis specialty care infrastructure. Moreover, adalimumab uveitis prescribing is most advanced in the US. In addition, corticosteroid implant adoption is established. Regional dominance is due to this combination of pricing environment and specialty care infrastructure.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Uveitis Market through 2034, driven by expanding adalimumab uveitis access across European healthcare systems and the active European clinical development in JAK inhibitor uveitis. The region is also witnessing biosimilar adalimumab access growing. Moreover, corticosteroid implant adoption is expanding. The combination of these demand drivers and clinical research network positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Uveitis Market was valued at USD 775.30 Mn in 2025 and is projected to reach USD 1,615.60 Mn by 2034, growing at a CAGR of 8.5% over the 2026–2034 forecast period.
The Uveitis Market is projected to grow at a CAGR of 8.5% from 2026 to 2034.
North America dominated the Uveitis Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for adalimumab uveitis and corticosteroid intravitreal implants and the established uveitis specialty care infrastructure.
The leading companies in the Uveitis Market include AbbVie, EyePoint Pharmaceuticals, Santen Pharmaceutical, Bausch + Lomb, Aldeyra Therapeutics, Clearside Biomedical.
Adalimumab visual i and visual ii phase iii 50 and 68 percent treatment failure rate reduction in active and inactive non-infectious uveitis has established the first fda-approved systemic biologic for non-infectious posterior and panuveitis that provides steroid-sparing sight-saving treatment.
By drug class, the corticosteroid and immunosuppressant segment dominated the Uveitis Market in 2025, as local steroid implants from AbbVie and EyePoint Pharmaceuticals anchored treatment of non-infectious uveitis, generating the largest share of the indication's revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.